28
Sun, Apr
27 New Articles

A decade ago, Austrian law firms stood out in terms of their regional presence in CEE. Wolf Theiss Partner Claus Schneider and CMS Managing Partner Johannes Juranek share insights into the growth trajectory of these regional law firms and the current landscape of the Austrian legal market.

This article is part of a series on developments in Austrian environment and climate change law in 2022 and, in particular, focuses on case law developments. For further details on legislative developments see, "Key developments in Austrian environment and climate change law in 2022: part one – legislation".

A spectre is haunting Europe – the spectre of… the Unitary Patent. With Germany having deposited its ratification document on 17 February 2023, this spectre is finally coming to life: the European Patent with Unitary Effect ("Unitary Patent") and the Unified Patent Court ("UPC") system will enter their preparatory phase. The actual launch date (the date as of which Unitary Patents will be in effect and actions can be filed with the UPC) is set for 1 June 2023.

2022 was a busy year marked by the late effects of the covid-19 pandemic and the Russia-Ukraine conflict. The latter has led to the rethinking of energy matters. Austrian legislation in 2022 was, therefore, characterised above all by new developments and amendments in energy law, with a focus on the expansion of renewable energy. This article is part of a series on developments in Austrian environment and climate change law in 2022 and, in particular, focuses on legislative developments.

Wolf Theiss has advised the JP Hospitality Investors Club and the JP Immobilien Group on two hotel development and lease agreements for projects in Kitzbuehel and Trieste. DSC Doralt Seist Csoklich and Graf von Westphalen reportedly advised the two hotel operators.

Wolf Theiss, working with Clifford Chance, has advised private equity investor Altor – on behalf of Altor Funds – on the acquisition of an 80% majority stake in Kommunalkredit Austria and entering into a partnership with the existing owners and the management of the bank.

The ascendant popularity of ESG across business sectors has also empowered the rise of its evil twin: greenwashing. To look at the interplay between the two and their implications for the pharma industry in CEE, we sat down with CMS Partners Gabriela Staber and Tomas Matejovsky. 

Our Latest Issue